Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 468

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 468
---
 | ​ 
 ​ | ​ |              ​ 
 March 31, 2025 | ​ | ​ |                 ​ 
 December 31, 2024 |
|:----------------------------------------|:--|:--|---------------:|:--|:--|------------------:|
| Raw materials                           | ​ | $ |          2,124 | ​ | $ |             2,124 |
| Work-in-process                         | ​ |   |            291 | ​ |   |               291 |
| ​                                       | ​ | ​ |          2,415 | ​ | ​ |             2,415 |
| Less Inventory Reserve for Obsolescence | ​ |   |         -1,515 | ​ |   |            -1,515 |
| Total                                   | ​ | $ |            900 | ​ | $ |               900 |

As of March 31, 2025 and December 31, 2024, inventory balances include inventory costs subsequent to regulatory approval of KORSUVA injection on August 23, 2021. There were write-downs of commercial supply inventory during each of the three months ended March 31, 2025 and 2024.

On December 17, 2024, in connection with the Merger Agreement, Cara and Cara Royalty Sub (the “Cara Sellers”) entered into an Asset Purchase Agreement (the “APA”) with Vifor Fresenius Medical Care Renal Pharma Ltd., pursuant to which, at the consummation of the Merger Agreement, Cara Sellers sold to CSL Vifor certain assets and rights for the development, manufacture and commercialization of difelikafalin as well as certain associated liabilities (the “Asset Disposition”), for a purchase price of $ (subject to certain adjustments with respect to inventory). Additionally, pursuant to the APA, at the consummation of the Asset Disposition, Cara paid CSL Vifor $ to compensate CSL Vifor for the estimated incremental future expenses incurred by CSL Vifor as a result of the transfer of the assets acquired and the liabilities assumed by it in connection with the Asset Disposition (see Note 18, Subsequent Events).

7. Prepaid expenses As of March 31, 2025, prepaid expenses were $ 1,592, consisting of $ 5of prepaid R&D clinical costs, $ 1,475of prepaid insurance and $ 112of other prepaid costs. As of December 31, 2024, prepaid